EpiBiologics is a biotech company developing tissue-selective extracellular protein degradation therapeutics using a proprietary modular bispecific antibody platform (EpiTAC).
The company focuses on targeted degradation of disease-driving membrane and soluble proteins to create novel therapies in oncology and immunology.
Leadership & Board
Current Number of Employees50
Current LinkedIn Followers5,374
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$107M
Total Amount Raised$107M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$107M
Latest Funding Amount$107M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
EpiBiologics had 50 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
50Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
EpiBiologics had 5,374 followers as of September 7, 2026. The number of followers increased by 7 (0.13%) week-over-week.
5,374Latest Followers Count
7(0.13%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.